Health Care [ 10/12 ] | Pharmaceuticals [ 66/74 ]
NASDAQ | Common Stock
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults.
It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.
Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | -0.25 Increased by 0.00% | -0.20 Decreased by -25.00% |
| Aug 7, 24 | -0.16 Increased by +64.44% | -0.19 Increased by +15.79% |
| May 7, 24 | -0.16 Increased by +65.22% | -0.32 Increased by +50.00% |
| Feb 22, 24 | -0.30 Increased by +33.33% | -0.44 Increased by +31.82% |
| Nov 2, 23 | -0.25 Increased by +56.14% | -0.57 Increased by +56.14% |
| Aug 3, 23 | -0.45 Increased by +51.09% | -0.59 Increased by +23.73% |
| May 4, 23 | -0.46 Increased by +41.03% | -0.61 Increased by +24.59% |
| Mar 1, 23 | -0.45 Increased by +57.14% | -0.59 Increased by +23.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 175.16 M Increased by +39.23% | -26.32 M Decreased by -8.52% | Decreased by -15.03% Increased by +22.06% |
| Jun 30, 24 | 161.39 M Increased by +46.55% | -16.22 M Increased by +62.09% | Decreased by -10.05% Increased by +74.13% |
| Mar 31, 24 | 144.87 M Increased by +52.92% | -15.25 M Increased by +65.39% | Decreased by -10.52% Increased by +77.37% |
| Dec 31, 23 | 131.51 M Increased by +50.41% | -28.58 M Increased by +23.29% | Decreased by -21.73% Increased by +49.00% |
| Sep 30, 23 | 125.81 M Increased by +75.05% | -24.26 M Increased by +54.66% | Decreased by -19.28% Increased by +74.10% |
| Jun 30, 23 | 110.13 M Increased by +99.96% | -42.78 M Increased by +49.04% | Decreased by -38.85% Increased by +74.52% |
| Mar 31, 23 | 94.73 M Increased by +172.57% | -44.05 M Increased by +38.92% | Decreased by -46.50% Increased by +77.59% |
| Dec 31, 22 | 87.43 M Increased by +242.66% | -37.25 M Increased by +56.55% | Decreased by -42.61% Increased by +87.32% |